Company news
Beyond Air, Inc. news in 2023
Beyond Air, Inc.'s news releases, calls and decks from 2023, newest first.
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
December 26, 2023
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
November 12, 2023
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 2, 2023
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
October 18, 2023
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2023
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH
October 15, 2023
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
September 26, 2023
Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
September 17, 2023
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
September 6, 2023
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024
August 9, 2023
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
August 6, 2023
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
July 23, 2023
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
June 21, 2023
Beyond Air® Secures up to $40 Million Debt Financing
June 14, 2023
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
June 14, 2023
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
May 15, 2023
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
April 18, 2023
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
March 22, 2023
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting
March 13, 2023
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
February 21, 2023
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023
February 8, 2023
Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer
January 29, 2023
Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
January 23, 2023
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
January 16, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 60 slides · June 2023